Choroidal thickness and visual prognosis in type 1 lesion due to neovascular age-related macular degeneration



To evaluate the association between subfoveal choroidal thickness and the visual outcome in eyes with type 1 choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD).


This was a retrospective, longitudinal, cross-sectional study including patients diagnosed with nAMD type 1 lesions managed with intravitreal injections of ranibizumab in a PRN strategy during 24 months. Retrospective chart review of patients with type 1 CNV recording the visual acuity, number of intravitreal injections, multimodal imaging data, and follow-up period was performed. Subfoveal choroidal thickness was measured using enhanced depth imaging scans obtained with spectral-domain optical coherence tomography.


Twenty-five eyes of 21 patients were included. The mean baseline logMAR best-corrected visual acuity was 0.52 (+0.35) (median 0.5; range 0.1-1; interquartile range (IQR) 0.3-0.8) and improved to 0.39 (+0.39) (median 0.4; range 0.1-1; IQR 0.2-0.5) by the end of the follow-up (p = 0.038). Subfoveal choroidal thickness was 202.8 (+60.3) μm (median 218; range 81-285; IQR 146-258). Statistical mixed effects model demonstrated an association between rate of improvement of visual acuity with subfoveal choroidal thickness after 24 months (p<0.001) (95% confidence interval 0.0002-0.0001 logMAR month μm); higher thickness values were correlated with better visual acuity.


Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up.

Eur J Ophthalmol 2017; 27(2): 196 - 200




Pablo Hernández-Martínez, Rosa Dolz-Marco, David Hervás-Marín, Maria Andreu-Fenoll, Roberto Gallego-Pinazo, José Fernando Arévalo

Article History


Financial support and conflict of interest: Rosa Dolz-Marco: speaker (Bloss, Heidelberg Engineering, Novartis); grant support (Alcon, Allergan, Angelini, Bayer, Novartis, Thea). Maria Andreu-Fenoll: grant support (Alcon, Allergan, Angelini, Bayer, Novartis, Thea). Roberto Gallego-Pinazo: consultant (Alcon, Bayer, Novartis); speaker (Alcon, Bloss, Heidelberg Engineering, Novartis); grant support (Alcon, Allergan, Angelini, Bayer, Novartis, Thea). J. Fernando Arévalo: personal fees from Second Sight LLC, personal fees from Springer SBM LLC, personal fees from Alcon Laboratories, personal fees from DORC International BV, personal fees from Bayer AG, outside the submitted work. Pablo Hernández-Martínez and David Hervás-Marín have no conflict of interest.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  •  Unit of Macula, Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia - Spain
  •  RETICS Oftared, Instituto de Salud Carlos III, Madrid - Spain
  •  Biostatistics Unit, Health Research Institute La Fe, Valencia - Spain
  •  Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD - USA

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.